Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma by Costa, Bruno Marques et al.
Clinical Studies
Reversing HOXA9 Oncogene Activation by PI3K Inhibition:
Epigenetic Mechanism and Prognostic Significance in
Human Glioblastoma
Bruno M. Costa1,2, Justin S. Smith1, Ying Chen1, Justin Chen1, Heidi S. Phillips3,
Kenneth D. Aldape4, Giuseppe Zardo1,5, Janice Nigro6, C. David James1,
Jane Fridlyand1, Rui M. Reis2, and Joseph F. Costello1
Abstract
HOXA genes encode critical transcriptional regulators of embryonic development that have been impli-
cated in cancer. In this study, we documented functional relevance and mechanism of activation of HOXA9
in glioblastoma (GBM), the most common malignant brain tumor. Expression of HOXA genes was investi-
gated using reverse transcription–PCR in primary gliomas and glioblastoma cell lines and was validated in
two sets of expression array data. In a subset of GBM, HOXA genes are aberrently activated within confined
chromosomal domains. Transcriptional activation of the HOXA cluster was reversible by a phosphoinostide
3-k inase (PI3K) inh ib i tor through an epigenet ic mechanism invo lv ing his tone H3K27
trimethylation. Functional studies of HOXA9 showed its capacity to decrease apoptosis and increase cellular
proliferation along with tumor necrosis factor–related apoptosis-including ligand resistance. Notably,
aberrant expression of HOXA9 was independently predictive of shorter overall and progression-free survival
in two GBM patient sets and improved survival prediction by MGMT promoter methylation. Thus, HOXA9
activation is a novel, independent, and negative prognostic marker in GBM that is reversible through
a PI3K-associated epigenetic mechanism. Our findings suggest a transcriptional pathway through
which PI3K activates oncogenic HOXA expression with implications for mTOR or PI3K targeted therapies.
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Introduction
Glioblastoma (GBM) is the most common and malignant
primary brain tumor in adults. With rare exception, the infil-
trative nature of GBM precludes surgical cure and adjuvant
therapies have achieved only modest benefit, with median
survival remaining ∼12 months (1). Specific molecular char-
acteristics of GBM can be used to define prognostic sub-
groups (2–4). MGMT promoter methylation (5, 6) is an
independent favorable prognostic factor for GBM patients
(3), but this marker does not fully account for the variability
in survival (3), and additional markers are needed to be used
for the prognosis of individual patients.
Homeobox genes encode transcription factors important
for antero-posterior patterning during embryogenesis.
In humans, there are 39 Class I homeobox (HOX) genes
found in four genomic clusters (HOXA at 7p15.3, HOXB at
17q21.3, HOXC at 12q13.3, and HOXD at 2q31). Their spatial
and temporal colinear expression pattern is critical for
body patterning during development (7, 8), and HOX genes
also have critical postdevelopmental regulatory functions
(9–12). Aberrant HOX gene expression initiates leukemias
(13, 14), contributes to multiple types of solid tumors
(15, 16), and has been detected in malignant astrocytomas
(17). Furthermore, HOXA9 and MEIS1 may be part of a
switch that regulates progenitor abundance by suppressing
differentiation and maintaining self-renewal during myelo-
poiesis (18). Thus, among the 39 HOX genes, HOXA9 is of
particular importance in leukemia and potentially other
cancers.
In the present study, we identify a subgroup of GBMs with
chromosomal domains of aberrant HOX gene activation,
show a mechanism by which this domain of activation is re-
versible, define an association between HOXA9 expression
and poor clinical outcome, and provide functional data on
the effects of HOXA9 in cell proliferation and apoptosis.
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Materials and Methods
Human tissues and glioma cell models. Human tissue
samples were obtained from the Neurosurgery Tissue Banks
at University of California, San Francisco (UCSF) and M.D.
Anderson Cancer Center (MDA) and would have been other-
wise discarded. Tumor samples were examined by a neuro-
pathologist to ensure that >90% of the tissue represented
tumor and classified according to current WHO guidelines
(19). All samples were collected with informed consent, and
investigations using human tissues and clinical data were ap-
proved by the institutional review boards of UCSF and MDA.
Initial exploratory survival analysis was performed on a set of
nine GBMs from UCSF. Validation of a trend between HOXA9
expression and poor survival was performed using two sets
of expression array data (Affymetrix U133 arrays or Affyme-
trix U95Av2 arrays), one set consisting of 37 GBM samples
from UCSF (20) and a second set composed of 63 GBMs from
MDA (ref. 21; Gene Expression Omnibus accession number
GSE4271). Combined assessment of HOXA9 expression and
MGMT promoter methylation was performed in 35 of the
37 GBMs from UCSF. Details of the tumor types and nontu-
mor samples are included in the online Supplementary Ma-
terials and Methods. The nine GBM cell lines (A172, LN18,
LN215, LN229, LN235, LN319, U87-MG, U178, and U373)
and immortalized human astrocytes (hTERT/E6/E7) were
maintained in DMEM with 10% fetal bovine serum, the neu-
rospheres were maintained in neurobasal medium supple-
mented with basic fibroblast growth factor and epidermal
growth factor (21), and the orthotopic xenografed GBMs
were derived as previously described (22–24).
In vitro analyses. RNA isolation, cDNA synthesis, reverse
transcription–PCR (RT-PCR), quantitative real-time PCR
(qPCR), and chromatin immunoprecipitation (ChIP) analyses
were performed by standard techniques in cell lines (Supple-
mentary Materials and Methods). DNA isolation, bisulfite
treatment, and analyses of MGMT promoter methylation in
primary tumor tissues from UCSF were performed as de-
scribed previously (3, 25) and are detailed in Supplementary
Materials and Methods. A172 cells and neurospheres were
treated with a phosphoinositide 3-kinase (PI3K) inhibitor
(LY294002) and rapamycin to investigate the mechanism reg-
ulating HOXA gene expression in GBM. Overexpression of
HOXA9 by retroviral infection and siRNA-mediated silencing
of HOXA9 were used to investigate the functional relevance
of HOXA9 expression, which was assessed by cell prolifera-
tion and apoptosis analyses (Supplementary Materials and
Methods).
Statistical analyses. The Kaplan-Meier method was
used to estimate overall survival (OS) and progression-free
survival (PFS), where OS was measured from the time of
surgical resection to death or the last date when the patient
was known to be alive, and PFS was defined as the time from
surgical resection to the time of shown tumor growth on
follow-up imaging or death, if death occurred before docu-
mented progression. Multivariate survival analyses by Cox
proportional hazard models (backward selection) were per-
formed to adjust for the effects of patient age and Karnofsky
performance status (KPS). A P value of <0.05 was considered
significant.
The two-sided Student's t test was used to assess statistical
differences in qPCR data and in vitro cell death and apoptosis
experiments. A repeated measures ANOVA was used to as-
sess differences in the cell proliferation curves.
To identify samples that express a given gene and assign
the confidence to each sample, we used model-based cluster-
ing to identify the mixture components. Analysis of gene ex-
pression microarray data, generation of heat maps for the
HOX clusters, and investigation of correlations between ex-
pression of HOXA9 and other transcripts are detailed in Sup-
plementary Materials and Methods.
Results
HOXA genes are predominantly activated in high-grade
astrocytoma. Initially, we assessed HOXA gene expression in
normal brain tissue, primary diffuse glioma tissue, and GBM-
derived cell lines using RT-PCR. Most HOXA genes were
not expressed in fetal and adult nontumoral brain tissues
(Fig. 1A). Similarly, of eight primary grade 2 and grade 3 glio-
mas, HOXA gene expression was evident in only two cases
(Fig. 1A). In contrast, all primary GBMs and cell lines showed
expression of multiple HOXA genes (Fig. 1A). Supplementary
Fig. S1A shows representative RT-PCR analyses of HOXA gene
expression in human astrocytoma samples, exemplifying tu-
mors that were positive or negative for expression of specific
HOXA genes. Collectively, these data suggest that aberrant
HOXA gene expression is a common feature of the most ma-
lignant gliomas, GBM, and infrequent in lower-grade gliomas.
HOXA9 was the only HOXA gene whose expression showed
a trend to associate with shorter survival of these nine GBM
patients (median survival of 9 versus 53 weeks, P = 0.06). Sup-
plementary Fig. S1 (B and C) suggests HOXA9 expression in
GBMs is not simply a reflection of the expression pattern of
the tumor cell(s) of origin nor a consequence of therapeutic
agents but rather represents an aberrant gene activation
event associated with tumor progression.
A confined chromosomal domain of transcriptional ac-
tivation encompasses HOXA expression in GBM. We next
analyzed expression of HOXA genes in two independent val-
idation sets of expression array data, one set of 37 GBMs
from UCSF (20) and a second set of 63 GBMs from MDA
(21). To investigate whether aberrant HOXA activation was
an isolated event, or part of a larger chromosomal mecha-
nism, we created heat maps for the HOXA cluster and sur-
rounding genes within 1 Mb in each direction (Fig. 1B). In
both sets, the HOXA cluster showed a distinct chromosomal
domain of activation such that many of the HOXA genes were
concurrently activated, whereas genes outside of the domain
were mostly silent (Fig. 1B). Similar domains of transcription-
al activation were also present in the HOXB, HOXC, and
HOXD clusters (Supplementary Fig. S2 and S3), suggesting
a common, coordinated activation of these domains.
Heat map analyses reflecting the expression pattern across
all four HOX clusters in UCSF and MDA tumor sets analyzed
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by expression arrays (Supplementary Fig. S4) revealed that
(a) a subset of GBMs shows widespread activation of HOX
genes, (b) the pattern of HOX activation is aberrant and does
not resemble the coordinated colinear expression observed
during normal embryonic development, (c) HOXA9 substan-
tially contributes to the clustering into two sample groups in
both data sets. To quantify which of the HOX genes account
for the clustering, the fold change between the two groups
for each gene was computed using the median value of the
genes in each group (Supplementary Table S1). The HOX
genes with statistically significant different expression be-
tween the two heat map cluster groups in both the UCSF
and MDA tumors are HOXA1-A5, HOXA7, HOXA9, HOXA10,
HOXB7, and HOXC6.
We used the ONCOMINE database to investigate addition-
al GBM expression array data sets for activation of the HOXA
domain (26). A subset of GBM patients showed a similar pro-
file of activation of HOXA genes in a study by Sun and collea-
gues (27). Expression of most HOXA genes, with the exception
of HOXA6 and HOXA13, showed a high positive correlation
with HOXA9 expression (Supplementary Table S2). HOXA11,
which did not show a statistically significant positive corre-
lation with HOXA9 expression in our tumor sets, also showed
a substantially lower correlation coefficient in the samples
from Sun and colleagues (27). Because HOXA6 and HOXA13
do not correlate with HOXA9 expression in all three tested
tumor sets, a mechanism of chromosomal amplification
encompassing the entire HOXA locus may not adequately
explain the presence of such transcriptionally active domains.
Furthermore, we confirmed in the UCSF set that aberrant
HOXA gene activation may be enhanced by, but is not reliant
on, increased chromosome 7p15.3 copy number (P = 0.5, data
not shown).
Inhibition of the PI3K pathway reverses aberrant tran-
scriptional activation of the HOXA cluster. In HeLa cells,
the PI3K signaling pathway can regulate EZH2 activity (28),
a key component of the polycomb repressor complex 2 that
promotes gene silencing by trimethylation of histone H3 ly-
sine 27 (H3K27-3met) on target genes. AKT-mediated phos-
phorylation of EZH2 inhibits its histone methyltransferase
activity, resulting in gene reactivation. Given that HOXA
genes are known targets of EZH2-mediated methylation in
some normal tissues (29) and that PTEN, a regulator of
PI3K activity, is frequently inactivated in GBM (30, 31), we
hypothesized that alterations in the PI3K pathway may be
upstream effectors of aberrant HOXA gene expression in
GBM. We first investigated a potential relationship between
PI3K signaling and HOXA9 expression in A172 cells, a GBM
cell line with PTEN homozygous deletion (32) and HOXA9 ac-
tivation. Consistent with the PI3K pathway having a regula-
tory function on HOXA9 expression, HOXA9 transcript levels
were significantly reduced in A172 cells after treatment with
the PI3K inhibitor LY294002 (Supplementary Fig. S5A). This
regulatory mechanism was reversible as HOXA9 was restored
to pretreatment levels 32 hours after A172 cells were placed
in fresh medium lacking LY294002 (Supplementary Fig. S5A).
The levels of HOXA9 protein were also decreased in
LY294002-treated cells at 24 h (Supplementary Fig. S5B).
Considering the concomitant activation of several HOXA
genes within domains of activation in primary GBMs, we hy-
pothesized that HOXA genes in GBM are activated by a
shared mechanism of transcriptional regulation. To address
this question, the entire HOXA cluster was tested for suppres-
sion by LY294002 treatment of A172 cells. Expression of most
HOXA genes was suppressed (range, 39–74%) after treatment
with LY294002, except for HOXA6 and HOXA13 (Fig. 2A);
these two HOXA genes also did not correlate with HOXA9 ex-
pression in our primary tumor sets (Supplementary Table S1)
or in the cohort studied by Sun and colleagues (27). These
data suggest that HOXA9 expression is reversibly regulatable
by the PI3K pathway in glioma cells and further suggest that
this regulation extends throughout most of the 100+ kb chro-
mosomal domain containing the HOXA cluster.
To further support our data implicating the PI3K path-
way as a critical regulatory mechanism of HOXA gene ex-
pression, we next searched the Connectivity Map data set
for drugs that induce gene expression signatures involving
HOXA9-associated genes (33). This analysis revealed com-
mon PI3K inhibitors, including LY294002 and Wortmannin,
as top hits significantly associated with the HOXA9-derived
gene expression signature (Supplementary Table S3 and
Supplementary Results: Connectivity Map analyses reveal
the PI3K pathway as a key regulator of HOXA genes expres-
sion). Additionally, in primary GBM xenografts derived from
18 patients, aberrant activation of HOXA9 was significantly
associated with PTEN gene inactivation [PTEN mutations
and homozygous deletion were previously examined by se-
quence analysis and multiplex PCR analysis, respectively
(22, 24)], further supporting the relevance of PI3K signaling
for the regulation of HOXA expression (Supplementary
Table S4 and Supplementary Results: aberrant expression
of HOXA9 is associated with PTEN gene inactivation in pri-
mary GBM xenografts).
Therapeutic agents that inhibit mTOR, a downstream me-
diator of the PI3K pathway, are currently in clinical trials for
GBM. To determine whether mTOR is a critical regulator of
HOXA gene expression, A172 cells were treated with rapamy-
cin, an inhibitor of mTOR activity, and the expression levels
of the HOXA genes were assessed by RT-PCR. Rapamycin
treatment resulted in a more modest inhibition of HOXA
transcripts levels (Fig. 2B), suggesting that the mechanism
by which the PI3K pathway regulates HOXA genes expression
is primarily independent of mTOR. HOXA9 protein levels
were also unaffected by rapamycin treatment as indicated
by immunoblotting analysis (Supplementary Fig. S5C).
To determine whether the PI3K-mediated regulation of
HOXA genes is also observed in other GBM cell lines, we test-
ed how LY294002 treatment affected HOXA9 levels by qPCR
in two sublines of a primary GBM grown in neurosphere con-
ditions, both of which presented detectable levels of endog-
enous HOXA9. Similarly to the observations in A172 cells, the
inhibition of PI3K in these neurospheres also repressed
HOXA9 mRNA levels (Supplementary Fig. S5D), whereas the
relationship between rapamycin and HOXA9 expression in
the very small number of neurosphere lines is not as consis-
tent (Supplementary Fig. S5E).
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PI3K-mediated regulation of HOXA9 gene expression oc-
curs through reversible epigenetic histone modifications.
To elucidate the downstream effectors of PI3K-mediated
regulation of HOXA gene expression and considering that
AKT mediates EZH2 histone methyltransferase activity in
HeLa cells, we assessed whether the regulatory role of the
PI3K pathway onHOXA9 expression could be linked to histone
modifications. ChIP analysis was performed on A172 cells
Figure 1. HOXA genes are activated predominantly in high-grade astrocytoma. A, percentage of HOXA genes with detectable levels of expression by
RT-PCR in normal brain tissue, in primary tumor tissue (astrocytoma WHO grades 2–4), and in established malignant GBM cell lines. Fetal brain gray (FBG)
matter and fetal brain white (FBW) matter are nonneoplastic tissues from human fetal brain. NB1 and NB8 are nonneoplastic adult brain specimens.
A, astrocytoma (WHO grade 2); AA, anaplastic astrocytoma (WHO grade 3); GBM, glioblastoma (WHO grade 4). B, gene expression heat maps centered on
the HOXA cluster and extending 1 Mb in each direction. Both UCSF (left, 37 tumors) and MDA (right, 63 tumors) sets show HOXA gene domains of
transcriptional activation, such that genes contained in the boundaries flanking the activated domains are relatively silent. One exception is SCAP2, located
∼200 kb outside of the HOXA cluster. The gray vertical bars indicate the approximate boundaries of the domain of activation. The colored bars across
the top of the heat maps indicate which tumors express HOXA9 [blue, high expression; yellow, low or no expression; white, samples for which the
expression status could not be assigned with high (>95%) confidence]. Red and green colors on the heat map reflect high and little/no expression of each
gene, respectively.
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Figure 2. The PI3K pathway regulates HOXA
cluster gene transcription in GBM through
reversible epigenetic histone modifications,
independently of mTOR. A, expression levels of
genes in the HOXA cluster by RT-PCR after
treatment of A172 cells with the PI3K inhibitor
LY294002. β-Actin and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) were used
as control genes. Values are ratios of expression
levels in treated/untreated A172 cells for each
HOXA gene. Expression of most HOXA genes,
except for HOXA6 and HOXA13, decreased
after PI3K inhibition. HOXA1 and HOXA9
expression was assessed for each of two
alternative splicing forms (i and ii). The results
are representative of three independent
experiments. B, expression levels of HOXA
genes after treatment with rapamycin, a specific
mTOR inhibitor. Data are presented similarly to
A. The results are representative of three
independent experiments. C, ChIP analysis of
the HOXA9 5′ region after LY294002-mediated
inhibition of PI3K. Top, diagram indicating the
locations of the primer sets used for ChIP
analysis. Bottom, PCR products for the three
regions after ChIP analysis in A172 cells treated
with LY294002 (+) or vehicle (−). The input
products reflect PCR on DNA not selected by
immunoprecipitation. The IgG reaction serves
as a negative control. The results are
representative of three independent
experiments.
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that were either untreated or treated with LY294002 for 24
hours. A172 cells treated with LY294002 showed reduced ex-
pression of HOXA9, as well as reduced H3K4 trimethylation
(a mark of active chromatin) and concomitant increased
H3K27 trimethylation (a mark of repressive chromatin) in
three different regions near the HOXA9 promoter (Fig. 2C).
When LY294002-treated cells were incubated for an additional
48 hours in fresh media without drug, HOXA9 expression,
H3K27 trimethylation, and H3K4 trimethylation returned to
pretreatment levels (data not shown). Collectively, these data
indicate that the regulatory role of the PI3K pathway on
HOXA9 expression is linked to epigenetic histone modifica-
tions that seem to be fully and expediently reversible in
GBM cells.
HOXA9 increases cell proliferation and inhibits apopto-
sis. To test the functional consequences ofHOXA9 overexpres-
sion in vitro, a GBM cell line (U87-MG) and immortalized
human astrocytes (hTERT/E6/E7) stably overexpressing
HOXA9 were established by retroviral infection and compared
with their counterparts infected with control vector, which do
not overexpress HOXA9 (Fig. 3A). The use of these two GBM
models allowed us to test the effect of HOXA9 overexpression
in tumoral (U87-MG) and immortalized but nontumoral
(hTERT/E6/E7) backgrounds. Expression of exogenous
HOXA9 was associated with a modest but consistent increase
in proliferation of hTERT/E6/E7 cells (Fig. 3B; P < 0.001) and a
decrease in their spontaneous apoptosis (Fig. 3C; P = 0.032)
compared with the parental cells. U87-MG cells stably expres-
sing exogenousHOXA9 consistently showed amodest increase
in proliferation, but only when the cells became more conflu-
ent (Fig. 3B; P < 0.001). HOXA9 expression in U87-MG cells also
decreased tumor necrosis factor–related apoptosis-inducing
ligand (TRAIL)–induced apoptosis (Fig. 3C; P = 0.009). These
data suggest that HOXA9 serves an antiapoptotic role in
immortalized human astrocytes and GBM cells, which may
affect cell number/proliferation. Conversely, the inhibition of
endogenous HOXA9 expression in A172 cells with siRNA
(Fig. 3D) resulted in increased spontaneous apoptosis
Figure 3. Expression of HOXA9 influences cell proliferation and apoptosis. A, immortalized human astrocytes (hTERT/E6/E7) and a GBM-derived cell
line (U87-MG) were retrovirally infected with a MSCV-HOXA9 construct or control vector and tested for HOXA9 expression by RT-PCR.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used for equal loading control. Successful expression of exogenous HOXA9 was detected for
both cell types. The two PCR bands for HOXA9 derive from amplification of specific alternative splicing isoforms. B, proliferation curves of hTERT/E6/E7 and
U87-MG cells after retroviral infections. Results are representative of three independent experiments, and each time point was counted in duplicate
(data points represent mean ± SD). Repeated measures ANOVA showed statistically significant differences between control cells and cells overexpressing
HOXA9 (hTERT/E6/E7/Control versus hTERT/E6/E7/HOXA9, F(1,18) = 92.7, P < 0.001; U87-MG/Control versus U87-MG/HOXA9, F(1,18) = 19.7, P < 0.001).
C, apoptosis analysis by Annexin V–FITC and propidium iodide staining followed by flow cytometry. Results are representative of three independent
experiments (averages ± SDs), each showing a similar effect relative to controls. *, P < 0.05, two-sided Student's t test (P = 0.032 for hTERT/E6/E7/Control
versus hTERT/E6/E7/HOXA9; P = 0.036 for spontaneous U87-MG/Control versus TRAIL-treated U87-MG/Control; P = 0.009 for TRAIL-treated
U87-MG/Control versus TRAIL-treated U87-MG/HOXA9). D, left, qPCR analysis of HOXA9 expression levels after treatment with siHOXA9 or siControl for
various time points. Expression levels were normalized to hGUS. *, P < 0.05, two-sided Student's t test (P = 0.004 for 24 h; P = 0.001 for 48 h). Right,
apoptosis analysis by Annexin V–FITC and propidium iodide staining followed by flow cytometry 48 h after siRNA treatments. The results are representative
of three independent experiments (averages ± SDs), each showing a similar effect relative to controls. *, P = 0.026, two-sided Student's t test.
Costa et al.
Cancer Res; 70(2) January 15, 2010 Cancer Research458
Research.
on October 16, 2020. © 2010 American Association for Cancercancerres.aacrjournals.orgDownloaded from 
Published OnlineFirst January 12, 2010; DOI: 10.1158/0008-5472.CAN-09-2189 
(Fig. 3D), further supporting an antiapoptotic role of HOXA9 in
GBM cells.
HOXA9 expression is associated with shorter OS and
PFS in GBM patients. Based on the association of HOXA9
with poor prognosis in the initial test set of nine GBM pa-
tients, we then performed survival analysis using the UCSF
and MDA sets of expression array data (21). To validate the
expression array data, RT-PCR for HOXA9 was performed on
the subsets of cases with the highest and lowest HOXA9
expression array values, and the results were concordant
(Fig. 4A and B, insets). In the UCSF cohort, GBM patients
whose tumors expressed HOXA9 (5 of 37, 14%) had a signif-
icantly shorter OS [median, 22 weeks; 95% confidence inter-
val (CI), 5–38 weeks] compared with those whose tumors
lacked expression of HOXA9 (median, 68 weeks; CI, 36–100
weeks; P < 0.0001; Fig. 4A). Similarly, in the MDA set, patients
whose tumors expressed HOXA9 (14 of 63, 22%) had a shorter
median OS (56 weeks; CI, 10–102 weeks) than those whose
tumors lacked HOXA9 expression (median OS, 91 weeks; CI,
46–136 weeks; P = 0.03; Fig. 4B). Patients whose tumors ex-
pressed HOXA9 also had significantly shorter PFS. Median
PFS was 4 weeks (CI = 4–5 weeks) and 30 weeks (CI = 22–
38 weeks) in the UCSF set and 46 weeks (CI = 17–76 weeks)
and 77 weeks (CI = 22–132 weeks) in the MDA set for patients
whose tumors did and did not express HOXA9, respectively (P
< 0.0001, Fig. 4C, UCSF set; P = 0.03, Fig. 4D, MDA set). These
associations remained statistically significant after adjusting
for the effects of patient age and KPS in the UCSF set (P =
0.006 for OS, P = 0.01 for PFS). KPS data were not available
for the MDA cohort.
HOXA9 expression status improves MGMT-based sur-
vival prediction in GBM patients. MGMT promoter methyl-
ation in tumor tissue is currently the most powerful
molecular prognostic indicator of favorable prognosis in
Figure 4. HOXA9 expression is associated with OS and PFS of GBM patients. A and B, Kaplan-Meier (KM) OS curves for GBM patients from UCSF (A) and
MDA (B), whose tumors do express (dotted line) and do not express (solid line) HOXA9, as assessed by expression array analysis. The inset provides
RT-PCR confirmation of HOXA9 expression status in tumors classified as nonexpressers (lanes 1–4 in the UCSF set; lanes 1–3 in the MDA set) and tumors
classified as expressers (lanes 5–8 in the UCSF set; lanes 4–6 in the MDA set), based on expression array analysis in each set. Vertical tic marks indicate
censored data time points. C and D, Kaplan-Meier PFS curves for the same GBM sets. Vertical tic marks indicate censored data time points.
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GBM (3). However, a significant subset of patients whose tu-
mors show MGMT promoter methylation do not experience
survival benefit. To contrast the prognostic significance of
HOXA9 expression with this biomarker standard, we per-
formed methylation-specific PCR analysis on DNA available
from 34 of the 37 UCSF GBMs previously analyzed by expres-
sion array (Fig. 1B) and from the original nine GBMs ana-
lyzed by RT-PCR (Fig. 1A). No DNA was available from the
MDA set to perform methylation-specific PCR. MGMT pro-
moter methylation was identified in 24 of the 43 cases
(56%; Supplementary Fig. S7); as expected (3), these patients
showed trends toward longer OS (P = 0.1; Fig. 5A) and PFS
(P = 0.06; Supplementary Fig. S6A) compared with those
whose tumors lackedMGMTmethylation. HOXA9 andMGMT
in combination showed statistically significant associations
with OS and PFS. Patients whose tumors showed HOXA9 ex-
pression and/or lack of MGMT promoter methylation had
significantly shorter OS (median, 31 weeks; CI, = 3–60 weeks)
and PFS (median, 13 weeks; CI, 5–20 weeks) compared with
patients whose tumors lacked HOXA9 expression and had
MGMT promoter methylation (median, 82 weeks; CI, 41–
123 weeks for OS; P = 0.002; Fig. 5B; median, 33 weeks; CI,
22–44 weeks for PFS; P = 0.001; Supplementary Fig. S6B).
These associations remained statistically significant after ad-
justing for the effects of patient age and KPS (P = 0.02 for OS,
P = 0.03 for PFS). Expression of HOXA9 was identified in five
(21%) of the tumors with a methylated MGMT promoter and,
among these patients, was associated with a significantly
shorter OS (median survival of 9 versus 98 weeks, P <
0.0001; Fig. 5C) and shorter PFS (median PFS of 4 versus 33
weeks, P < 0.0001; Supplementary Fig. S6C).
Discussion
Multiple HOX genes have been shown to be overexpressed
in GBM cell lines and primary astrocytomas (17), suggesting
a role for these genes in gliomagenesis. However, the me-
chanisms underlying HOX activation, in addition to their
functional relevance in GBM cells, have not been explored.
Our results define PI3K-regulatable chromosomal domains
of transcriptional activation as a means of aberrant gene ex-
pression in cancer. This adds to a growing perspective on
chromosomal domains of epigenetic silencing in normal
and malignant cells (34–36). The domains of HOXA transcrip-
tional activation we discovered have notable features: (a)
they involve an important set of genes, which have critical
roles in embryonic development, normal adult tissue func-
tion, and oncogenesis; (b) they are mediated through revers-
ible epigenetic histone modifications that are regulatable
through the PI3K pathway, a pathway known to be frequently
altered in many cancers (37); and (c) they include aberrant
expression of the oncogenic HOXA9 (13, 38), associated with
histologic malignant progression, shorter time to tumor pro-
gression and shorter OS in GBM patients. Our functional da-
ta provide further support for an oncogenic role of HOXA9 in
GBM. Furthermore, a recent study suggested HOX genes may
be part of a glioma stem cell signature with prognostic sig-
nificance in GBM patients treated with concomitant chemor-
adiotherapy (16). Our data identify PI3K pathway dysfunction
as a potential driver of this signature and suggest the exciting
possibility that PI3K inhibitors may allow therapeutic rever-
sal of the core element of this cancer stem cell signature.
We implicate the PI3K pathway in the generation of aber-
rant HOXA domains of activation in GBM. Activation of the
PI3K pathway in glioma is significantly associated with in-
creasing tumor grade, decreased apoptosis, and adverse clin-
ical outcome (37). In addition, PTEN, a central regulator of
the PI3K pathway, is frequently altered in GBM and, when
altered in lower-grade gliomas, portends a dismal prognosis
(1). Although multiple downstream mediators of the PI3K
pathway have been described and much focus is placed on
translational effects of PI3K pathway dysregulation, we pro-
pose that the pathway arm involving EZH2, a central mem-
ber of the polycomb repressive complexes with intrinsic
Figure 5. HOXA9 expression improves MGMT-based survival prediction of GBM patients. A, Kaplan-Meier OS curve for 43 GBM patients from UCSF
(including cases used for expression array analysis and those used for initial assessment of HOXA expression) whose tumors showed (solid line) or lacked
(dotted line) MGMT promoter methylation. B, Kaplan-Meier OS curve for the same set as in A, based on HOXA9 expression and MGMT promoter
methylation status. C, Kaplan-Meier OS curve for the 24 patients whose tumors showed MGMT promoter methylation, stratified based on whether the
tumors expressed HOXA9.
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histone methyltransferase activity (39), mediates the PI3K-
dependent transcriptional regulation ofHOXA9 and potentially
the whole HOXA cluster and many other genes. Akt-mediated
phosphorylation of EZH2 suppresses trimethylation of lysine
27 in histone H3 (H3K27) by interfering with the ability of the
EZH2 complex to interact with histone H3, leading to dere-
pression of silenced genes (28). EZH2 can increase cancer cell
proliferation when overexpressed (40), is associated with me-
tastasis in prostate cancer (41), and is expressed at signifi-
cantly higher levels in GBM tissue versus noncancerous
brain tissue (26, 27) and low-grade gliomas (26, 42). Further-
more, EZH2 itself was among the genes that showed coex-
pression with HOXA9 based on expression array data from
both UCSF and MDA tumor sets. However, the activity of
overexpressed EZH2 may well be inhibited by Akt-mediated
phosphorylation. Regulation of HOXA expression is even
more complex, involving other histone marks, noncoding
RNA, and microRNA-mediated regulation depending on the
cellular context (43). Because epigenetic mechanisms are
interdependent, PI3K-driven changes in H3K27 methylation
may influence additional histone modifications, either direct-
ly or indirectly. In fact, the PI3K pathway has been linked to
other specific histone modifications, such as H3K9 demethy-
lation (44), acetylation of H3K9 and H3K18 (45), and deace-
tylation of H3K14 (45). Thus, therapeutic agents targeting
components of the PI3K pathway may indirectly affect the
histone marks of tumor cells. We hypothesize that particular
profiles of histone modifications, in conjunction with the sta-
tus of the PI3K pathway, may influence therapeutic decisions
in the future. Indeed, whereas the histone profile of malig-
nant cells is not currently used to direct therapeutic deci-
sions, histone modifications are strongly correlated with
clinical outcome of tumor patients (46–50).
Considerable focus has been placed on developing chemo-
therapeutic agents to inhibit mTOR, a downstream effector
of the PI3K pathway that is an important regulator of cell
growth and metabolism (51). Whereas these agents are ex-
pected to suppress the growth effects of the mTOR pathway,
it is less clear whether mTOR is a factor regulating the ex-
pression of HOXA genes in GBM. If these domains of tran-
scriptional activation contribute to tumor growth in vivo,
mTOR inhibitors alone may be suboptimal for improving
the outcome in a subset of GBM patients. PI-103, a recently
reported agent that dually inhibits PI3K and mTOR in glioma
cells (52) or similar agents may prove more efficacious.
MGMT promoter methylation is a favorable prognostic in-
dicator in GBM but is limited in its clinical applicability to
individual patients. HOXA9 expression is a marker of poor
prognosis, independent of MGMT promoter methylation sta-
tus, and identifies a subset of the patients who, despite ap-
parently favorable MGMT promoter methylation, have poor
outcomes. Thus, the combined assessment of HOXA9 expres-
sion and MGMT methylation status in GBM may prove to be
a promising effective prognostic tool. The grade specificity of
HOXA9 expression according to histology and the association
with poor outcome among GBM patients suggest that it may
be useful as part of a molecular-based classification of glio-
mas. The prognostic relevance of HOXA9 expression in new
experimental therapies warrants further investigation.
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